In vivo assessment of the host reactions to the biodegradation of the two novel magnesium alloys ZEK100 and AX30 in an animal model.
In vivo assessment of the host reactions to the biodegradation of the two novel magnesium alloys ZEK100 and AX30 in an animal model.
复制标题
DOI：
10.1186/1475-925x-11-14
复制
发表时间：
2012-03-20
影响因子：
3.9
通讯作者：
Meyer-Lindenberg A
中科院分区：
文献类型：
--
作者：
Huehnerschulte TA;Reifenrath J;von Rechenberg B;Dziuba D;Seitz JM;Bormann D;Windhagen H;Meyer-Lindenberg A
最近发表的关于可生物降解镁植入物的大多数研究使用镁钙合金或镁铝稀土合金。然而，由于稀土是元素的混合物，其毒性尚不清楚，因此减少稀土的含量是有利的。本研究评估了两种新的镁合金的体内生物相容性，这两种镁合金具有减少的含量（ZEK 100）或完全不含稀土（AX 30）。将24只家兔随机分为4组（AX30或ZEK 100，分别为3或6个月），并在其胫骨中插入圆柱形钉。为了评估生物降解，进行μCT扫描和组织学检查。μCT扫描显示，直到第三个月，ZEK 100的降解速度都比AX 30快，但这种差异在6个月后趋于平衡。组织学显示，两种材料均诱导不良宿主反应和受体骨中大量破骨细胞。两种材料组的矿物沉积率都很高。这两种合金都显示出良好的降解特性，但它们会引起不良的宿主反应，即破骨细胞驱动的骨吸收和随后的新骨骨膜形成。因此，ZEK100和AX30的生物相容性值得怀疑，需要进一步研究，重点是细胞水平上的相互作用。
Most studies on biodegradable magnesium implants published recently use magnesium-calcium-alloys or magnesium-aluminum-rare earth-alloys. However, since rare earths are a mixture of elements and their toxicity is unclear, a reduced content of rare earths is favorable. The present study assesses the in vivo biocompatibility of two new magnesium alloys which have a reduced content (ZEK100) or contain no rare earths at all (AX30). 24 rabbits were randomized into 4 groups (AX30 or ZEK100, 3 or 6 months, respectively) and cylindrical pins were inserted in their tibiae. To assess the biodegradation μCT scans and histological examinations were performed. The μCT scans showed that until month three ZEK100 degrades faster than AX30, but this difference is leveled out after 6 months. Histology revealed that both materials induce adverse host reactions and high numbers of osteoclasts in the recipient bone. The mineral apposition rates of both materials groups were high. Both alloys display favorable degradation characteristics, but they induce adverse host reactions, namely an osteoclast-driven resorption of bone and a subsequent periosteal formation of new bone. Therefore, the biocompatibility of ZEK100 and AX30 is questionable and further studies, which should focus on the interactions on cellular level, are needed.